|[December 11, 2012]
PerkinElmer Expands Reagent Portfolio to Accelerate Biotherapeutics Drug Development
WALTHAM, Mass. --(Business Wire)--
Inc., a global leader focused on improving the health and safety of
people and the environment, today announced the launch of a new range of assay
kits utilizing AlphaLISA® technology to help improve the
safety testing, manufacturing and quality control of biotherapeutic
Biotherapeutic drug development is a rapidly growing field due to the
highly targeted and specific nature of these drugs, which are
particularly beneficial for the treatment of patients with cancer,
inflammatory disease and rare diseases. Biotherapeutics are naturally
occurring molecules, such as antibodies, recombinant proteins and
vaccines, and are recognized as an alternative to small-molecule
approaches for drug development.
Regulatory requirements addressing potentially harmful side effects and
undesirable contaminants that can lead to toxic reactions or adverse
immune responses are more stringent for biotherapeutic drugs than for
small molecule drugs. PerkinElmer carefully developed these new assays
to meet these more stringent performance requirements relating to drug
impurities and toxic effects.
"PerkinElmer is continuously seeking new ways to improve human health
through the devlopment of innovative technologies," said Kevin
Hrusovsky, President, Life Sciences and Technology, PerkinElmer.
"Adverse reactions due to drug toxicity is a real issue that we are
passionate about helping to minimize. We are very excited to enable our
customers to improve the safety and efficacy of new biotherapeutic drugs
being developed through our new assay kits which are the latest addition
to our growing biotherapeutics portfolio."
The kits use PerkinElmer's AlphaLISA
technology to achieve higher quality
results than the comparable ELISA (enzyme-linked immunosorbent assay)
technology in half the time, helping to accelerating the drug discovery
process. AlphaLISA technology also has a simple protocol with fewer
assay steps compared to standard ELISA, resulting in better inter- and
intra-assay precision, greatly improved coefficient of variations (CVs),
and easier method transfer to downstream departments due to reduced
PerkinElmer has a portfolio of solutions across the biotherapeutics
workflow, from target identification, cloning and expression to safety
testing and quality control. The portfolio includes the LabChip®
GXII benchtop microfluidic system for high throughput protein
analysis and characterization, and the JANUS®
BioTx Pro™ Workstation for protein purification with batch and
column chromatography capabilities.
For more information about PerkinElmer's biotherapeutics solutions,
please visit: http://www.perkinelmer.com/biotherapeutics.
About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and
safety of people and the environment. The company reported revenue of
approximately $1.9 billion in 2011, has about 7,000 employees serving
customers in more than 150 countries, and is a component of the S&P 500
Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
[ Back To IBM News 's Homepage ]